• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Cormac Sheridan

Cormac Sheridan

Articles

ARTICLES

Spinout From Roche Italian Research Unit Raises EUR22M

April 3, 2002
By Cormac Sheridan
Italy’s first major biotechnology start-up of the year is a spinout from the Milan research unit of F. Hoffmann-La Roche Ltd. BioXell SpA, which was formed at the beginning of January, held a public launch last week and disclosed its first-round funding of EUR22 million (US$19.3 million). (BioWorld International)
Read More

U.S. Research Foundation Backs Swedish Stem Cell Program

March 27, 2002
By Cormac Sheridan

U.S. Research Foundation Backs Swedish Stem Cell Program

March 27, 2002
By Cormac Sheridan

Genmab To Collaborate With Bionomics On Angiogenesis

March 20, 2002
By Cormac Sheridan

Genmab To Collaborate With Bionomics On Angiogenesis

March 20, 2002
By Cormac Sheridan

NeuroSearch, GlaxoSmithKline Halt Development Of NS2389

March 13, 2002
By Cormac Sheridan
The antidepressant drug development alliance between Danish firm NeuroSearch A/S and partner GlaxoSmithKline plc has hit a bump that will delay progress by several years. The two companies have decided to discontinue development of the neurotransmitter reuptake inhibitor NS2389, which had been in Phase II clinical trials. (BioWorld International)
Read More

NeuroSearch, GlaxoSmithKline Halt Development Of NS2389

March 13, 2002
By Cormac Sheridan
The antidepressant drug development alliance between Danish firm NeuroSearch A/S and partner GlaxoSmithKline plc has hit a bump that will delay progress by several years. The two companies have decided to discontinue development of the neurotransmitter reuptake inhibitor NS2389, which had been in Phase II clinical trials. (BioWorld International)
Read More

Biovitrum Plans Phase IIb Trials Of Obesity Treatment BVT.933

March 6, 2002
By Cormac Sheridan

Elan Continuing With Alzheimer’s Vaccine Program Despite Setback

March 6, 2002
By Cormac Sheridan

Biovitrum Plans Phase IIb Trials Of Obesity Treatment BVT.933

March 6, 2002
By Cormac Sheridan
View All Articles by Cormac Sheridan

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 20, 2025.
  • Brain, syringe hovering over hands

    NICE rejects Lilly‘s Kisunla and Eisai‘s Leqembi

    BioWorld
    To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe